Shaanxi Kanghui Pharmaceutical Co.,Ltd.

The company was founded in 1999, completed the shareholding system reform in 2009, and listed on the A-share main board of the Shanghai Stock Exchange on April 21, 2017. It is a national high-tech enterprise integrating pharmaceutical R&D, production and sales, and a national intellectual property demonstration enterprise. The company currently has a number of wholly-owned and holding subsidiaries, covering fields such as drug distribution, Chinese medicine tablets, chemical intermediates (fermentation, synthesis), medical devices, and private equity funds. The company's main business covers pharmaceutical manufacturing and pharmaceutical distribution. The business covers R&D, production and sales of proprietary Chinese medicines, Chinese medicine tablets, chemical intermediates, and wholesale distribution of biological products, blood products, pharmaceuticals and Chinese herbal medicines. The company's main products include anti-silver granules, compound double flower tablets, Kun Fu Kang capsules (tablets), bone acupuncture capsules, bone pain capsules with cinnamon, anti-aging granules, jujube seed anshen granules, and menopausal capsules. Corporate honors: Awarded the BRICS variety with the most market potential in 2017, advanced unit for torch statistics in 2016, law-abiding and honest enterprise in 2016, top 100 credit enterprises in Shaanxi in 2015, etc.